Instantaneous inhibitory potential and inhibitory quotient show a modest association with virologie outcome: Is either a useful surrogate for clinical drug efficacy?

Clinical Infectious Diseases

Volumn 51, Issue 1, 2010, Pages 99-100

  MacArthur, Rodger D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INHIBITORY QUOTIENT; INSTANTANEOUS INHIBITORY POTENTIAL; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77953729579     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653431     Document Type: Note

References (11)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 1 December 2009: 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 14 March 2010.
2. Henrich TJ, Ribaudo HJ, Kuritzkes DR. Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HlV-1 response to antiretroviral therapy. Clin Infect Dis 2010; 51(1): 93-98.
3. Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimize pharmacotherapy. Lancet Infect. Dis 2006; 6: 215-225
4. Shen L, Peterson S, Sedaghat AR, et al. Doseresponse curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14: 762-766 (Pubitemid 351951518)
5. Shen L, Rabi SA, Siliciano RF. A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci 2009; 30: 610-616
6. Boffito M, Dickinson L, Hill A, et al. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antivir Ther 2004; 9: 423-429 (Pubitemid 38878758)
7. Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviralexperienced, HIV-1-infected patients. AIDS 2009; 23: 357-368
8. Moltó J, Santos JR, Pérez-Alvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008; 52: 3928-3932
9. Clevenbergh P, Garraffo R, Durant J. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002; 16: 2311-2315 (Pubitemid 35449017)
10. Demeter LM, Mukherjee AL, DiFrancesco R, et al. The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral- experienced HIV-infected patients. HIV Clin Trials 2008; 9: 61-72. (Pubitemid 351214242)
11. Ying H, Lin F, MacArthur RD, et al. A fuzzy discrete event system approach to determining optimal HIV/AIDS treatment regimens. IEEE Trans Inf Technol Biomed 2006; 10: 663-676 (Pubitemid 44604896)